Better-Than-Expected Earnings: CNX Midstream Partners LP reported fourth-quarter 2019 earnings per unit of 76 cents, ahead of the Zacks Consensus Estimate of 58 cents.
Estimate Revision Trend & Surprise History: The stock had seen the Zacks Consensus Estimate for fourth-quarter earnings remain essentially unmoved over the last 60 days
Coming to earnings surprise history, the natural gas midstream infrastructure operator is on a solid footing, having gone past the Zacks Consensus Estimate in three of the last four reports, with the average positive surprise being 13.27%. This is shown in the chart below:
Revenues: Revenues of $81.5 million beat the Zacks Consensus Estimate of $75.8 million.
Key Stats: Full-year 2019 sales for the Anchor Systems unit (which handles natural gas midstream facilities in the Marcellus Shale and Utica Shale in Pennsylvania and West Virginia) was $296.1 million, up from the year-ago revenue of $240.4 million.
In the twelve-month period, the partnership’s gathered volumes of dry and wet gas rose to 859 and 659 billion British thermal units per day (BBtu/d), from 716 BBtu/d and 554 BBtu/d, respectively, in 2018.
CNX Midstream Partners reported that its distributable cash flow (DCF) for fourth-quarter 2019 came in at $48.4 million, up 13.3% from the year-ago quarter.
Zacks Rank: Currently, CNX Midstream Partners carries a Zacks Rank #4 (Sell).
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Image: Bigstock
CNX Midstream (CNXM) Q4 Earnings Beat, DCF Increases Y/Y
Better-Than-Expected Earnings: CNX Midstream Partners LP reported fourth-quarter 2019 earnings per unit of 76 cents, ahead of the Zacks Consensus Estimate of 58 cents.
Estimate Revision Trend & Surprise History: The stock had seen the Zacks Consensus Estimate for fourth-quarter earnings remain essentially unmoved over the last 60 days
Coming to earnings surprise history, the natural gas midstream infrastructure operator is on a solid footing, having gone past the Zacks Consensus Estimate in three of the last four reports, with the average positive surprise being 13.27%. This is shown in the chart below:
CNX Midstream Partners LP Price and EPS Surprise
CNX Midstream Partners LP price-eps-surprise | CNX Midstream Partners LP Quote
Revenues: Revenues of $81.5 million beat the Zacks Consensus Estimate of $75.8 million.
Key Stats: Full-year 2019 sales for the Anchor Systems unit (which handles natural gas midstream facilities in the Marcellus Shale and Utica Shale in Pennsylvania and West Virginia) was $296.1 million, up from the year-ago revenue of $240.4 million.
In the twelve-month period, the partnership’s gathered volumes of dry and wet gas rose to 859 and 659 billion British thermal units per day (BBtu/d), from 716 BBtu/d and 554 BBtu/d, respectively, in 2018.
CNX Midstream Partners reported that its distributable cash flow (DCF) for fourth-quarter 2019 came in at $48.4 million, up 13.3% from the year-ago quarter.
Zacks Rank: Currently, CNX Midstream Partners carries a Zacks Rank #4 (Sell).
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>